Gilead Sciences Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

Gilead Sciences Inc. (NASDAQ:GILD)’s Financial Overview

Gilead Sciences Inc. (NASDAQ:GILD) surged 0.44% yesterday to close its trading session at $74.87. The company has 1 year Price Target of $95.74. Gilead Sciences Inc. has 52-Week high of $105.57 and 52-Week Low of $71.39. The stock touched its 52-Week High on Dec 2, 2015 and 52-Week Low on Nov 4, 2016. The stock traded with the volume of 7.14 Million shares yesterday. The firm shows the market capitalization of $98.64 Billion.

Gilead Sciences Inc. (NASDAQ:GILD) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $2.75/share against the analyst consensus estimate of $2.86/share. The difference between the actual and expected EPS is $-0.11 a share with a surprise factor of -3.8%.

The firm is trading with SMA20 of -0.12 Percent, SMA50 of -1.34 Percent and SMA200 of -9.9 percent. Gilead Sciences Inc. has P/S value of 3.12 while its P/B value stands at 5.87. Similarly, the company has Return on Assets of 29.3 percent, Return on Equity of 93.7 percent and Return on Investment of 45.9 Percent. The company shows Gross Margin and Operating Margin of 86.5 percent and 60.8 percent respectively.

Many brokerage firms are involved in issuing their ratings on Gilead Sciences Inc. (NASDAQ:GILD). On 14-Nov-16 Stifel Initiated Gilead Sciences Inc. Stock  to Buy. Another firm also rated the stock on 8-Nov-16 where Mizuho Initiated the stock to Buy.

The Stock currently has Analyst’ mean Recommendation of 2.2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 22 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 99.00, with a high estimate of 118.00 and a low estimate of 81.00. The median estimate represents a +32.23% increase from the last price of 74.87.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Netflix, Inc. (NASDAQ:NFLX)

Netflix is the world’s leading Internet television network with millions of subscribers in nearly 50 countries who have access to an ever-expanding library of TV shows and movies, including original programming, documentaries and feature films. The company offers the ability to watch as subscribers want, anytime, anywhere, on nearly any Internet-connected screen.

Netflix, Inc. (NASDAQ:NFLX)’s Financial Outlook

The 36 analysts offering 12-month price forecasts for Netflix have a median target of 132.00, with a high estimate of 165.00 and a low estimate of 60.00. The median estimate represents a +12.33% increase from the last price of 117.51.

Netflix, Inc. is estimated to report earnings on  01/17/2017. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 14 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.13.  The reported EPS for the same quarter last year was $0.07.

According to Zacks Investment Research, Netflix, Inc. has a Consensus Recommendation of 2.31. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 0.5% and closed its last trading session at $117.51. The company has the market capitalization of $50.43 Billion. The stock has 52-week high of $133.27 and 52-Week low of $79.95. The firm touched its 52-Week high on Dec 7, 2015 and 52-Week low on Feb 8, 2016. The company has volume of 7.08 Million shares. The company has a total of 429.15 Million shares outstanding.

Netflix, Inc. (NASDAQ:NFLX) in the last quarter reported its actual EPS of $0.12/share where the analyst estimated EPS was $0.06/share. The difference between the actual and Estimated EPS is $0.06. This shows a surprise factor of 100 percent.

The company has YTD performance of 2.74 percent. Beta for Netflix, Inc. stands at 1.67 while its ATR (average true range) is 3. The company has Weekly Volatility of 1.58%% and Monthly Volatility of 2.61%%.

Netflix, Inc. has distance from 20-day Simple Moving Average (SMA20) of -1.1%, Distance from 50-Day Simple Moving Average of 5.01 percent and Distance from 200-Day Simple Moving Average of 17.57%.

The Company currently has ROA (Return on Assets) of 1.4 percent, Return on Equity (ROE) of 6.9 Percent and Return on Investment (ROI) of 6.2% with Gross margin of 31.2 percent and Operating & Profit margin of 3.5% and 2% respectively.